Raptor Pharmaceutical Corp. (NASDAQ:RPTP)’s share price shot up 2.7% during mid-day trading on Friday . The company traded as high as $6.05 and last traded at $6.02, with a volume of 362,596 shares. The stock had previously closed at $5.86.

A number of equities analysts have weighed in on RPTP shares. Zacks Investment Research downgraded shares of Raptor Pharmaceutical Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, May 3rd. FBR & Co reaffirmed a “hold” rating on shares of Raptor Pharmaceutical Corp. in a research note on Sunday, June 12th. JMP Securities downgraded shares of Raptor Pharmaceutical Corp. to a “hold” rating in a research note on Sunday, March 20th. Leerink Swann decreased their target price on shares of Raptor Pharmaceutical Corp. from $18.00 to $15.00 and set an “outperform” rating for the company in a research note on Monday, March 28th. Finally, Oppenheimer Holdings Inc. reaffirmed a “market perform” rating on shares of Raptor Pharmaceutical Corp. in a research note on Monday, April 11th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $11.00.

The stock’s market capitalization is $513.54 million. The firm’s 50 day moving average is $5.53 and its 200 day moving average is $4.69.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last posted its quarterly earnings data on Thursday, May 5th. The company reported ($0.17) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.17). During the same period last year, the company earned ($0.24) earnings per share. The firm earned $27.47 million during the quarter, compared to analysts’ expectations of $27.17 million. The business’s revenue for the quarter was up 34.3% compared to the same quarter last year. On average, analysts forecast that Raptor Pharmaceutical Corp. will post ($0.98) EPS for the current fiscal year.

A hedge fund recently raised its stake in Raptor Pharmaceutical Corp. stock. Cornerstone Capital Management Holdings LLC. increased its position in Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 319.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 251,803 shares of the company’s stock after buying an additional 191,703 shares during the period. Cornerstone Capital Management Holdings LLC. owned 0.30% of Raptor Pharmaceutical Corp. worth $1,310,000 at the end of the most recent reporting period.

Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company’s product, PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.